Skip to content
Life Sciences Series B Founded 2018

Tavotek

Provider of drug discovery platform for different diseases. The products are TBE monoclonal and multispecific antibodies against unique targets, TIM synthetic biologic design for auto-immune diseases, and chronic viral infections MIP unique multi-cyclic peptides with great potency targeting intracellular protein-protein interactions. The company was founded in 2018 and headquartered in King Of Prussia, United…

📍 King Of Prussia, United States · Oncology,

Funding snapshot

Last roundSeries B
Amount$35M
Date20 November 2021
Total raised$35M
Team size8

About

Provider of drug discovery platform for different diseases. The products are TBE monoclonal and multispecific antibodies against unique targets, TIM synthetic biologic design for auto-immune diseases, and chronic viral infections MIP unique multi-cyclic peptides with great potency targeting intracellular protein-protein interactions. The company was founded in 2018 and headquartered in King Of Prussia, United States. It has raised $35M in series b funding, with backing from CS Capital, fontuscapital.com, Yuanbio Venture Capital, Yuanhe Holdings, and others. The company operates in the Life Sciences - Oncology, Life Sciences - Life Sciences Platforms and Tools, Life Sciences - Genomics space. Its offerings span Oncology - Drugs - Diversified - Immuno Oncology and Genomics - Applied Genomics - Synthetic Biology.

Business model

Oncology > Drugs > Diversified > Immuno Oncology,

Genomics > Applied Genomics > Synthetic Biology,

Life Sciences Platforms and Tools > Research Services > Genomics

Institutional investors

CS Capital fontuscapital.com Yuanbio Venture Capital Yuanhe Holdings New Alliance Capital GF Xinde Investment Management CTS Capital Juming Venture Capital

Latest coverage

No articles yet.

Raising like Tavotek?

Analyze your pitch deck before your next raise.

Analyze My Deck →